Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients

Obesity Surgery

Volumn 24, Issue 5, 2014, Pages 765-770

  Griffo, E ^a   Nosso, G ^a   Lupoli, R ^a   Cotugno, M ^a   Saldalamacchia, G ^a   Vitolo, G ^a   Angrisani, L ^b   Cutolo, P P ^b   Rivellese, A A ^a   Capaldo, B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b General and Laparoscopic Surgery Unit   (Italy)

Author keywords

Active GLP 1; Bariatric surgery; Lipid metabolism; Postprandial triglycerides

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GENERAL CONDITION IMPROVEMENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; ROUX EN Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; BARIATRIC SURGERY; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HYPERLIPIDEMIAS; METABOLISM; MIDDLE AGED; OBESITY, MORBID; TREATMENT OUTCOME;

ADULT; BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPERLIPIDEMIAS; INCRETINS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY, MORBID; POSTPRANDIAL PERIOD; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84898035583     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-1148-z     Document Type: Article

References (32)

1. Gumbs AA, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15(4):462-73.
2. Vetter ML, Ritter S, Wadden TA, et al. Comparison of bariatric surgical procedures for diabetes remission: efficacy and mechanisms. Diabetes Spectr. 2012;25(4):200-10.
3. Dixon JB, le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379(9833):2300-11.
4. Lima MM, Pareja JC, Alegre SM, et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871-5.
5. Camastra S, Gastaldelli A, Mari A, et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia. 2011;54:2093-102.
6. Vila M, Ruíz O, Belmonte M, et al. Changes in lipid profile and insulin resistance in obese patients after Scopinaro biliopancreatic diversion. Obes Surg. 2009;19(3):299-306.
7. Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143(4):897-912.
8. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57.
9. Madsbad S. The role of GLP-1 impairment in obesity and potential therapeutic implications. Diabetes Obes Metab. 2013. doi: 10.1111/dom.12119.
10. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24(4):345-50.
11. Stefater MA, Sandoval DA, Chambers AP, et al. Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology. 2011;141(3):939-49. e1-4.
12. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol. 2012;23(1):56-61.
13. Zambon S, Romanato G, Sartore G, et al. Bariatric surgery improves atherogenic LDL profile by triglyceride reduction. Obes Surg. 2009;19(2):190-5.
14. Garcia-Marirrodriga I, Amaya-Romero C, Ruiz-Diaz GP, Férnandez S, et al. Evolution of lipid profiles after bariatric surgery. Obes Surg. 2012;22(4):609-16.
15. Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22(8):1268-75.
16. Vix M, Diana M, Liu KH, et al. Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial. Obes Surg. 2013;23(5):613-21.
17. Saboya C, Arasaki CH, Matos D, et al. Relationship between the preoperative body mass index and the resolution of metabolic syndrome following Roux-en-Y gastric bypass. Metab Syndr Relat Disord. 2012;10(4):292-6.
18. Jamal M, Wegner R, Heitshusen D, Liao J, Samuel I. Resolution of hyperlipidemia follows surgical weight loss in patients undergoing Roux-en-Y gastric bypass surgery: a 6-year analysis of data. Surg Obes Relat Dis. 2011;7(4):473-9.
19. Tinahones FJ, Queipo-Ortuño MI, Clemente-Postigo M, et al. Postprandial hypertriglyceridemia predicts improvement in insulin resistance in obese patients after bariatric surgery. Surg Obes Relat Dis. 2013;9(2):213-8.
20. Hady HR, Dadan J, Gołaszewski P, Safiejko K. Impact of laparoscopic sleeve gastrectomy on body mass index, ghrelin, insulin and lipid levels in 100 obese patients. Wideochir Inne Tech Malo Inwazyjne. 2012;7(4):251-9.
21. Moustarah F, Gilbert A, Després JP, Tchernof A. Impact of gastrointestinal surgery on cardiometabolic risk. Curr Atheroscler Rep. 2012;14(6):588-96.
22. Benetti A, Del Puppo M, Crosignani A, et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures. Diabetes Care. 2013;36(6):1443-7.
23. Qin X, Shen H, Liu M, Yang Q, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G943-9.
24. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212(1):217-22.
25. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53(3):552-61.
26. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-52.
27. Malandrucco I, Pasqualetti P, Giordani I, et al. Very-low-calorie diet: a quick therapeutic tool to improve β cell function in morbidly obese patients with type 2 diabetes. Am J Clin Nutr. 2012;95(3):609-13.
28. Chambers AP, Jessen L, Ryan KK, et al. Weight independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141:950-8.
29. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479-85.
30. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the metabolic syndrome - an allostatic perspective. Biochim Biophys Acta. 2010;1801(3):338-49.
31. Schinner S, Scherbaum WA, Bornstein SR, et al. Molecular mechanisms of insulin resistance. Diabet Med. 2005;22(6):674-82. Review.
32. Mingrone G, DeGaetano A, Greco AV, et al. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia. 1997;40(5):599-605.